Literature DB >> 3103297

OKT3 in the reversal of acute hepatic allograft rejection.

C O Esquivel, J J Fung, B Markus, S Iwatsuki, R D Gordon, L Makowka, J W Marsh, A G Tzakis, S Todo, T E Starzl.   

Abstract

OKT3 was an effective immunosuppressant agent in patients with acute cell-mediated allograft rejection that had not responded to initial steroid therapy. OKT3 was also valuable for treating patients with early hepatic graft dysfunction caused by other factors than rejection. In such recipients, the doses of CyA can be greatly reduced, allowing recovery of frequently damaged kidneys while maintaining effective immunosuppression.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3103297      PMCID： PMC2904687     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


  5 in total

1.  ORTHOCLONE OKT3 in Treatment of Allografts Rejected Under Cyclosporine-Steroid Therapy.

Authors:  T E Starzl; J J Fung
Journal:  Transplant Proc       Date:  1986-08       Impact factor: 1.066

Review 2.  Evolution of liver transplantation.

Authors:  T E Starzl; S Iwatsuki; D H Van Thiel; J C Gartner; B J Zitelli; J J Malatack; R R Schade; B W Shaw; T R Hakala; J T Rosenthal; K A Porter
Journal:  Hepatology       Date:  1982 Sep-Oct       Impact factor: 17.425

3.  Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.

Authors:  A B Cosimi; R C Burton; R B Colvin; G Goldstein; F L Delmonico; M P LaQuaglia; N Tolkoff-Rubin; R H Rubin; J T Herrin; P S Russell
Journal:  Transplantation       Date:  1981-12       Impact factor: 4.939

4.  Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen.

Authors:  A J Demetris; S Lasky; D H Van Thiel; T E Starzl; A Dekker
Journal:  Am J Pathol       Date:  1985-01       Impact factor: 4.307

5.  Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts.

Authors:  A B Cosimi; R B Colvin; R C Burton; R H Rubin; G Goldstein; P C Kung; W P Hansen; F L Delmonico; P S Russell
Journal:  N Engl J Med       Date:  1981-08-06       Impact factor: 91.245
  5 in total
  9 in total

1.  Rabbit monoclonal antibody: potential application in cancer therapy.

Authors:  Lifeng Feng; Xian Wang; Hongchuan Jin
Journal:  Am J Transl Res       Date:  2011-04-23       Impact factor: 4.060

2.  Effect of OKT3 on survival and rate of retransplantation.

Authors:  B H Markus; J J Fung; R D Gordon; S Iwatsuki; C O Esquivel; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-08       Impact factor: 1.066

Review 3.  Liver transplantation--the first 25 years.

Authors:  H L Ascher
Journal:  West J Med       Date:  1988-09

4.  Indications for pediatric liver transplantation.

Authors:  C O Esquivel; S Iwatsuki; R D Gordon; W W Marsh; B Koneru; L Makowka; A G Tzakis; S Todo; T E Starzl
Journal:  J Pediatr       Date:  1987-12       Impact factor: 4.406

5.  Transplantation for primary biliary cirrhosis.

Authors:  C O Esquivel; D H Van Thiel; A J Demetris; A Bernardos; S Iwatsuki; B Markus; R D Gordon; J W Marsh; L Makowka; A G Tzakis
Journal:  Gastroenterology       Date:  1988-05       Impact factor: 22.682

6.  Liver transplantation in children.

Authors:  R W Busuttil; P Seu; J M Millis; K M Olthoff; J R Hiatt; A Milewicz; B Nuesse; G el-Khoury; D Raybould; A Nyerges
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

7.  Use of OKT3 monoclonal antibody as induction therapy for control of rejection in liver transplantation.

Authors:  W J Wall; C N Ghent; A Roy; V C McAlister; D R Grant; P C Adams
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

8.  Liver transplantation. Experience with 100 cases.

Authors:  J L Szpakowski; K Cox; P Nakazato; W Concepcion; B Levin; C O Esquivel
Journal:  West J Med       Date:  1991-11

9.  Experience with Orthoclone OKT3 monoclonal antibody in liver transplantation.

Authors:  R D Gordon; A G Tzakis; S Iwatsuki; S Todo; C O Esquivel; J W Marsh; A Stieber; L Makowka; T E Starzl
Journal:  Am J Kidney Dis       Date:  1988-02       Impact factor: 8.860
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.